Steinert Disease clinical trials at University of California Health
2 in progress, 1 open to eligible people
Showing trials for
Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
open to eligible people ages 16 years and up
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).
at UCSD
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Sorry, accepting new patients by invitation only
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
at UCLA
Last updated: